A review of the clinical pharmacokinetics and pharmacodynamics of Varenicline for smoking cessation

Clinical Pharmacokinetics

Volumn 49, Issue 12, 2010, Pages 799-816

  Faessel, Hélène M ^a   Obach, R Scott ^a   Rollema, Hans ^a   Ravva, Patanjali ^a   Williams, Kathryn E ^a   Burstein, Aaron H ^a  

^a PFIZER INC   (United States)

Author keywords

Drug interactions; Nicotinic receptor agonists, pharmacodynamics; Nicotinic receptor agonists, pharmacokinetics; Pharmacokinetic pharmacodynamic relationships; Population pharmacokinetics; Smoking cessation therapies, pharmacodynamics; Smoking cessation therapies, pharmacokinetics; Varenicline, drug interactions; Varenicline, pharmacodynamics; Varenicline, pharmacokinetics.

Indexed keywords

AMFEBUTAMONE; CIMETIDINE; CYTOCHROME P450; DIGOXIN; LANOXICAP; METFORMIN; NICOTINE; UNCLASSIFIED DRUG; VARENICLINE; WARFARIN;

AGING; ANTICOAGULANT THERAPY; BODY WEIGHT; CLINICAL PHARMACOLOGY; CLINICAL PRACTICE; CLINICAL TRIAL; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ELDERLY CARE; FATIGUE; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NICOTINE REPLACEMENT THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RACE; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; SMOKING CESSATION; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOBACCO DEPENDENCE; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANIMALS; BENZAZEPINES; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MIDDLE AGED; NICOTINIC AGONISTS; QUINOXALINES; SMOKING CESSATION; YOUNG ADULT;

EID: 78349277396     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11537850-000000000-00000     Document Type: Review

References (71)

1. World Health Organization [WHO]. WHO report on the global tobacco epidemic, 2008: theMPOWERpackage. Geneva: WHO, 2008 [online]. Available from URL: http://whqlibdoc.who.int/publications/2008/9789241596282-eng.pdf [Accessed 2010 Sep 23]
2. Mathers C, Loncar D. Projections of global mortality and burden of disease from 2002-2030. PLoS Med 2006; 3: 2011-30 (Pubitemid 44875937)
3. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004; 99: 29-38
4. Centers for Disease Control and Prevention. Cigarette smoking among adults: United States, 1998. MMWR Morb Mortal Wkly Rep 2000; 49 (39): 881-4
5. Stolerman IP, Shoaib M. The neurobiology of tobacco addiction. Trends Pharmacol Sci 1991; 12: 467-73
6. Rose JE, Behm FM. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments. Nicotine Tob Res 2004; 6: 523-32
7. Foll BL, Goldberg SR. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends Pharmacol Sci 2005; 26 (6): 287-93
8. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services, 2008May [online]. Available from URL: http://www.ahrq.gov/path/tobacco.htm [Accessed 2010 Sep 23]
9. Silagy C, Lancaster T, Stead LF, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3): CD000146
10. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; (1): CD000031
11. Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci 2007; 28 (7): 316-25
12. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an a4b2 nicotinic acetylcholine partial receptor agonist, vs placebo or sustainedrelease bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 56-63
13. Gonzales D, Rennard SI, NidesM, et al. Varenicline, an a4b2 nicotinic acetylcholine partial receptor agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 47-55
14. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006; 296 (1): 64-7115.
15. Williams KE, Reeves KR, Billing Jr CB, et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. CurrMed Res Opin 2007; 23 (4): 793-801
16. Berrie C. Doctor's guide: global edition. Varenicline effective in smoking cessation for smokers with chronic diseases: presented at ERS [commentary; online]. Available from URL: http://www.pslgroup.com/dg/22E672.htm [Accessed 2010 Oct 12]
17. Pfizer Labs. Chantix- (varenicline) tablets: product information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/ label/2009/021928s012s013lbl.pdf [Accessed 2010 Sep 23]
18. European Medicines Agency. Champix: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000699/WC500025251.pdf [Accessed 2010 Sep 23]
19. Tonstad S, Davies S, Flammer M, et al. Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline. Drug Saf 2010; 33 (4): 289-301
20. Fagerström K, Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat 2008; 4 (2): 353-63
21. Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother 2007; 7 (2): 121-7
22. Cahill K, Stead L, Lancaster T. A preliminary benefit-risk assessment of varenicline in smoking cessation. Drug Saf 2009; 32 (2): 119-35
23. Gunnell D, IrvineD,Wise L, et al. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. BMJ 2009; 339: b3805
24. Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science 2004; 306: 1029-32
25. Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the 2 subunits are involved in the reinforcing properties of nicotine. Nature 1998; 391 (Jan): 173-7
26. Coe JW, Brooks PR, VetelinoMG, et al. Varenicline: a novel, potent, and a4b2 selective nicotinic receptor partial agonist as an aid for smoking cessation. J Med Chem 2005; 48: 3474-7
27. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the a4b2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985-94
28. Rollema H, Shrikhande A, Ward KM, et al. Preclinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol 2010; 160: 334-45
29. Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nature Rev Drug Disc 2007; 6 (9): 746-62
30. Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav 2008; 32 (6): 664-75
31. Faessel HM, Smith BJ, Gibbs MA, et al. Single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers. J Clin Pharmacol 2006; 46 (9): 991-8
32. Faessel HM, Gibbs MA, Clark DJ, et al. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 2006; 46 (12): 1439-48
33. Burstein AH, Fullerton T, Clark DJ, et al. Pharmacokinetics, safety and tolerability following single and multiple oral doses of varenicline in elderly smokers. J Clin Pharmacol 2006; 46 (11): 1234-40
34. Xiao Y, Lv Y, Zhang X, et al. The pharmacokinetic and tolerability profile of varenicline in healthy Chinese volunteers. Int J Clin Pharmacol Ther 2009; 47 (4): 246-54
35. Zhao Q, Schwam E, Fullerton T, et al. Pharmacokinetics, safety and tolerability following multiple oral doses of varenicline under various titration schedules in elderly nonsmokers. J Clin Pharmacol. Epub 2010 May 13
36. Kikkawa H, Maruyama N, Fujimoto Y, et al. Single and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. J Clin Pharmacol. Epub 2010 Jun 15
37. Faessel HM, Burstein AH, Troutman MD, et al. Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers. Eur J Clin Pharmacol 2008; 64: 1101-9
38. Ravva P, Gastonguay MR, Tensfeldt TG, et al. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 2009; 68 (5): 669-81
39. Data on file, Pfizer Inc., 1998
40. Feng B, Obach RS, Burstein AH, et al. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: an in vitro-in vivo study. Clin Pharmacol Ther 2008; 83 (4): 567-76
41. Data on file, Pfizer Inc., 2004
42. Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos 2005; 4 (1): 121-30
43. Burstein AH, Clark DJ, O'Gorman M, et al. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study. J Clin Pharmacol 2007; 47: 1421-9
44. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41
45. Darmady EM, Offer J, Woodhouse AM. The parameters of the ageing kidney. J Path 1972; 109: 195-207
46. Davies DF, Shock NW. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adultmales. J Clin Invest 1950; 29: 496-507
47. Mayersohn MB. Chapter 9: special pharmacokinetic considerations in the elderly. In: William E, Evans JJS, William J, et al., editors. Applied pharmacokinetics principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1992: 1-43
48. Milsap RL, Hill MR, Szefler SJ. Chapter 10: special pharmacokinetic considerations in children. In: William E, Evans JJS, William J, et al., editors. Applied pharmacokinetics: principles of therapeutic drug monitoring. 3rd ed. Vancover (WA): Applied Therapeutics, Inc., 1992: 1-32
49. Faessel HM, Ravva P, Williams KE. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2009; 31 (1): 177-89
50. Urakami Y, Okada M, Masuda S, et al. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther 1998; 287: 800-5
51. Somogyi A, McLean A, Heinzow B. Cimetidine-procainamide pharmacokinetic interaction in man: evidence of competition for tubular secretion of basic drugs. Eur J Clin Pharmacol 1983; 25: 339-45
52. Somogyi A, Stockley C, Keal J, et al. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23: 545-51
53. Fletcher CV, Henry WK, Noormohamed SE, et al. The effect of cimetidine and ranitidine administration with zidovudine. Pharmacotherapy 1995; 15: 701-8
54. Fish DN, Chow AT. The clinical pharmacokinetics of levofloxacin. Clin Pharmacokinet 1997; 32: 101-19
55. Abel S, Nichols DJ, Brearley CJ, et al. Effect of cimetidine and ranitidine on pharmacokinetics and pharmacodynamics of a single dose of dofetilide. Br J Clin Pharmacol 2000; 49: 64-71
56. Masereew R, RusselFGM.Mechanisms and clinical implications of renal drug excretion. Drug Metab Rev 2001; 33: 299-351
57. Kimura N,Masuda S, Tanihara Y, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20 (5): 379-86
58. Kimura N, Okuda M, Inui K. Metformin transport by basolateral organic cation transporter hOCT2. Pharm Res 2005; 22: 255-9
59. Dresser MJ, Xiao G, Leabman MK, et al. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002; 19: 1244-7
60. Physicians' desk reference 2009. 63rd ed. New York: Thomson Reuters, 2009
61. Hsyu PH, Singh A,Giargiari TD, et al. Pharmacokinetics of bupropion and its metabolites in cigarette smokers versus nonsmokers. J Clin Pharmacol 1997; 37: 737-43 (Pubitemid 27449283)
62. Homsy W, Yan K, Houle JM, et al. Plasma levels of nicotine and safety of smokers wearing transdermal delivery systems during multiple simultaneous intake of nicotine and during exercise. J Clin Pharmacol 1997; 37: 728-36
63. Zevin S, Jacob P, Benowitz NL. Dose-related cardiovascular and endocrine effects of transdermal nicotine. Clin Pharmacol Ther 1998; 64 (1): 87-95
64. Data on file, Pfizer Inc., 2005
65. Ravva P, Gastonguay MR, French JL, et al. Quantitative assessment of exposure-response relationships for the efficacy and tolerability of varenicline for smoking cessation. Clin Pharmacol Ther 2010; 87 (3): 336-44
66. Rollema H, Faessel HM, Williams KE. Varenicline overdose in a teenager: a clinical pharmacology perspective. Clin Toxicol (Phila) 2009; 47 (6): 605
67. Tett SE, Kirkpatrick CM, Gross AS, et al. Principles and clinical applications of assessing alterations in renal elimination pathways. Clin Pharmacokinet 2003; 42 (14): 1193-211
68. Matzke GR, Frye RF. Drug administration in patients with renal insufficiency: minimizing renal and extrarenal toxicity. Drug Saf 1997; 16 (30): 205-31
69. Matzke GR, Millikin SP. Chapter 8: influence of renal function and dialysis on drug disposition. In: William E, Evans JJS, William J, et al., editors. Applied pharmacokinetics principles of therapeutic drug monitoring. 3rd ed. Vancouver (WA): Applied Therapeutics, Inc., 1992: 1-49
70. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: an update. Clin Pharmacokinet 1999; 36 (6): 425-38
71. Aubin H-J, Bobak A, Britton JR. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008; 63: 717-24